To prevent the subsequent S1P-receptor-dependent T cell egress of effector OT-I cells (60, 61), which may also contain Rgs1 expressing effector cells (56) from secondary lymphoid organs to the site of intestinal infection, the sphingosine1-phosphate receptor analogue FTY720 (Fingolimod, 25μg/mouse) was administered i.p. during the re-challenge period (at day 28, day 30, and day 32 post primary infection) (Figure 6A). This evidence concerns the gene RGS1 and digestive system infectious disorder.